{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:21:28Z","timestamp":1790814088821,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-INBS-0002"],"award-info":[{"award-number":["ANR-11-INBS-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD, AstraZeneca and Lundbeck managed by INSERM-Transfert"},{"DOI":"10.13039\/501100011000","name":"Mission Interminist\u00e9rielle de Lutte Contre les Drogues et les Conduites Addictives","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12889-019-6933-8","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T13:03:59Z","timestamp":1557839039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTANCES cohort"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-5083","authenticated-orcid":false,"given":"Guillaume","family":"Airagnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Lemogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Renuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Hoertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Roquelaure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Limosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Zins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"issue":"10","key":"6933_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","volume":"18","author":"G Airagnes","year":"2016","unstructured":"Airagnes G, Pelissolo A, Lavallee M, Flament M, Limosin F. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep. 2016;18(10):89.","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"6933_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.psc.2017.01.005","volume":"40","author":"N Ait-Daoud","year":"2017","unstructured":"Ait-Daoud N, Blevins D, Khanna S, Sharma S, Holstege CP. Women and addiction. Psychiatr Clin N Am. 2017;40(2):285\u201397.","journal-title":"Psychiatr Clin N Am"},{"key":"6933_CR3","unstructured":"AFSSAPS: Etat des lieux de la consommation de benzodiaz\u00e9pines en France. Rapport d'expertise. 2012."},{"issue":"5","key":"6933_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152\u20135.","journal-title":"Aust Prescr"},{"issue":"10","key":"6933_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","volume":"5","author":"J Jankovic","year":"2006","unstructured":"Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864\u201372.","journal-title":"Lancet Neurol"},{"issue":"2","key":"6933_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3109\/13651500903447810","volume":"14","author":"J Donoghue","year":"2010","unstructured":"Donoghue J, Lader M. Usage of benzodiazepines: a review. Int J Psychiatry Clin Pract. 2010;14(2):78\u201387.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"2","key":"6933_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","volume":"77","author":"M Lader","year":"2014","unstructured":"Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295\u2013301.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"6933_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.addbeh.2012.05.017","volume":"37","author":"T Nordfj\u00e6rn","year":"2012","unstructured":"Nordfj\u00e6rn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users. Addict Behav. 2012;37(10):1151\u20137.","journal-title":"Addict Behav"},{"issue":"8","key":"6933_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"TA Kurko","year":"2015","unstructured":"Kurko TA, Saastamoinen LK, Tahkapaa S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, Airaksinen MS, Hietala J. Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. Eur Psychiatry. 2015;30(8):1037\u201347.","journal-title":"Eur Psychiatry"},{"key":"6933_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/B978-0-12-800212-4.00102-3","volume-title":"Neuropathology of Drug Addictions and Substance Misuse. Edn","author":"J Micallef","year":"2016","unstructured":"Micallef J, Frauger E, Lapeyre-Mestre M. Chapter 102 - misuse of benzodiazepines in France A2 - Preedy, victor R. In: Neuropathology of Drug Addictions and Substance Misuse. Edn. San Diego: Academic Press; 2016. p. 1101\u201311."},{"issue":"8","key":"6933_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/pds.1763","volume":"18","author":"L Orriols","year":"2009","unstructured":"Orriols L, Salmi LR, Philip P, Moore N, Delorme B, Castot A, Lagarde E. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf. 2009;18(8):647\u201358.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6933_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pnpbp.2012.09.001","volume":"40","author":"A Konopka","year":"2013","unstructured":"Konopka A, Pe\u0142ka-Wysiecka J, Grzywacz A, Samochowiec J. Psychosocial characteristics of benzodiazepine addicts compared to not addicted benzodiazepine users. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;40:229\u201335.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"6933_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/acps.12909","volume":"138","author":"V Tapiainen","year":"2018","unstructured":"Tapiainen V, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM. The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case-control study. Acta Psychiatr Scand. 2018;138(2):91\u2013100.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"6933_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1192\/bjp.bp.114.149252","volume":"205","author":"V Kapil","year":"2014","unstructured":"Kapil V, Green J, Le Lait C, Wood D, Dargan P. Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatry. 2014;205(5):407\u20138.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"6933_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2125.2010.03818.x","volume":"71","author":"L Manthey","year":"2011","unstructured":"Manthey L, van Veen T, Giltay EJ, Stoop JE, Neven AK, Penninx BWJH, Zitman FG. Correlates of (inappropriate) benzodiazepine use: the Netherlands study of depression and anxiety (NESDA). Br J Clin Pharmacol. 2011;71(2):263\u201372.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"6933_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s11096-007-9183-2","volume":"30","author":"GB Ten Wolde","year":"2008","unstructured":"Ten Wolde GB, Dijkstra A, Van Empelen P, Knuistingh Neven A, Zitman FG. Psychological determinants of the intention to educate patients about benzodiazepines. Pharm World Sci. 2008;30(4):336\u201342.","journal-title":"Pharm World Sci"},{"issue":"3","key":"6933_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/15563650701586397","volume":"46","author":"B Glintborg","year":"2008","unstructured":"Glintborg B, Olsen L, Poulsen H, Linnet K, Dalhoff K. Reliability of self-reported use of amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, and opiates among acutely hospitalized elderly medical patients. Clin toxicol (Philadelphia, Pa). 2008;46(3):239\u201342.","journal-title":"Clin toxicol (Philadelphia, Pa)"},{"issue":"9","key":"6933_CR18","first-page":"917","volume":"141","author":"U Busto","year":"1989","unstructured":"Busto U, Lanctot K, Isaac P, Adrian M. Benzodiazepine use and abuse in Canada. CMAJ. 1989;141(9):917.","journal-title":"CMAJ"},{"issue":"1","key":"6933_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-publhealth-031210-100700","volume":"32","author":"DP Jutte","year":"2011","unstructured":"Jutte DP, Roos LL, Brownell MD. Administrative record linkage as a tool for public Health Research. Annu Rev Public Health. 2011;32(1):91\u2013108.","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"6933_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jad.2008.01.011","volume":"110","author":"K Demyttenaere","year":"2008","unstructured":"Demyttenaere K, Bonnewyn A, Bruffaerts R, De Girolamo G, Gasquet I, Kovess V, Haro JM, Alonso J. Clinical factors influencing the prescription of antidepressants and benzodiazepines:: results from the European study of the epidemiology of mental disorders (ESEMeD). J Affect Disord. 2008;110(1):84\u201393.","journal-title":"J Affect Disord"},{"issue":"11","key":"6933_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/pds.1827","volume":"18","author":"JHA Van der Heyden","year":"2009","unstructured":"Van der Heyden JHA, Gisle L, Hesse E, Demarest S, Drieskens S, Tafforeau J. Gender differences in the use of anxiolytics and antidepressants: a population based study. Pharmacoepidemiol Drug Saf. 2009;18(11):1101\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"6933_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/02813432.2015.1117282","volume":"33","author":"I Fride Tvete","year":"2015","unstructured":"Fride Tvete I, Bj\u00f8rner T, Skomedal T. Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway. Scand J Prim Health Care. 2015;33(4):252\u20139.","journal-title":"Scand J Prim Health Care"},{"issue":"3","key":"6933_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.drugalcdep.2011.09.002","volume":"121","author":"B Redonnet","year":"2012","unstructured":"Redonnet B, Chollet A, Fombonne E, Bowes L, Melchior M. Tobacco, alcohol, cannabis and other illegal drug use among young adults: the socioeconomic context. Drug Alcohol Depend. 2012;121(3):231\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"6933_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugalcdep.2014.06.020","volume":"142","author":"F Lugoboni","year":"2014","unstructured":"Lugoboni F, Mirijello A, Faccini M, Casari R, Cossari A, Musi G, Bissoli G, Quaglio G, Addolorato G. Quality of life in a cohort of high-dose benzodiazepine dependent patients. Drug Alcohol Depend. 2014;142:105\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"6933_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.eurger.2012.04.007","volume":"3","author":"E Holm","year":"2012","unstructured":"Holm E, Fosbol E, Pedersen H, Jensen TB, Nielsen M, Weeke P, Brinth L, Torp-Pedersen C. Benzodiazepine use in Denmark 1997\u20132008. Eur Geriatr Med. 2012;3(5):299\u2013303.","journal-title":"Eur Geriatr Med"},{"issue":"10","key":"6933_CR26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/14740338.2016.1221922","volume":"15","author":"A Morel","year":"2016","unstructured":"Morel A, Grall-Bronnec M, Bulteau S, Chauvin-Grelier P, Gailledrat L, Pinot ML, Jolliet P, Victorri-Vigneau C. Benzodiazepine dependence in subjects with alcohol use disorders: what prevalence? Expert Opin Drug Saf. 2016;15(10):1313\u20139.","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"6933_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s10654-015-0096-4","volume":"30","author":"M Zins","year":"2015","unstructured":"Zins M, Goldberg M. The French CONSTANCES population-based cohort: design, inclusion and follow-up. Eur J Epidemiol. 2015;30(12):1317\u201328.","journal-title":"Eur J Epidemiol"},{"issue":"36","key":"6933_CR28","first-page":"622","volume":"35","author":"GHE Santin","year":"2016","unstructured":"Santin GHE, Gu\u00e9guen A, Carton M, Cyr D, Genreau M, et al. Estimation de pr\u00e9valences dans Constances : premi\u00e8res explorations. Bull Epid\u00e9miol Hebd. 2016;35(36):622\u20139.","journal-title":"Bull Epid\u00e9miol Hebd"},{"issue":"8","key":"6933_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"6933_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000434755","volume":"84","author":"JM Cloos","year":"2015","unstructured":"Cloos JM, Bocquet V, Rolland-Portal I, Koch P, Chouinard G. Hypnotics and Triazolobenzodiazepines - best predictors of high-dose benzodiazepine use: results from the Luxembourg National Health Insurance Registry. Psychother Psychosom. 2015;84(5):273\u201383.","journal-title":"Psychother Psychosom"},{"key":"6933_CR31","unstructured":"Airagnes G, Lemogne C, Olekhnovitch R, Roquelaure Y, Hoertel N, Goldberg M, Limosin F, Zins M. Work-related stressors and increased risk of benzodiazepine long-term use: findings from the CONSTANCES population-based cohort. Am J Public Health. 0(0):e1\u20137."},{"key":"6933_CR32","first-page":"365","volume-title":"Comparative Social Research","author":"Silke L. Schneider","year":"2013","unstructured":"Schneider SL: The International Standard Classification of Education 2011. In: Class and Stratification Analysis (Comparative Social Research, Volume 30) Emerald Group Publishing Limited. Edn. Edited by Birkelund GE; 2013: 365\u2013379."},{"issue":"5","key":"6933_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.respe.2011.03.061","volume":"59","author":"AJ Morin","year":"2011","unstructured":"Morin AJ, Moullec G, Maiano C, Layet L, Just JL, Ninot G. Psychometric properties of the Center for Epidemiologic Studies Depression Scale (CES-D) in French clinical and nonclinical adults. Revue d'epidemiologie et de sante publique. 2011;59(5):327\u201340.","journal-title":"Revue d'epidemiologie et de sante publique"},{"key":"6933_CR34","volume-title":"AUDIT: the alcohol use disorders identification test: guidelines for use in primary health care","author":"TF Babor","year":"2001","unstructured":"Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: the alcohol use disorders identification test: guidelines for use in primary health care, 2 edn. Geneva: World Health Organization; 2001.","edition":"2"},{"issue":"7","key":"6933_CR35","first-page":"669","volume":"14","author":"CD Newgard","year":"2007","unstructured":"Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research--part 2: multiple imputation. Acad Emerg Med Off J Soc Acad Emerg Med. 2007;14(7):669\u201378.","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med"},{"issue":"3","key":"6933_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0197-2456(98)00005-1","volume":"19","author":"P Boudes","year":"1998","unstructured":"Boudes P. Drug compliance in therapeutic trials: a review. Control Clin Trials. 1998;19(3):257\u201368.","journal-title":"Control Clin Trials"},{"key":"6933_CR37","unstructured":"Les chiffres cl\u00e9s de la S\u00e9curit\u00e9 sociale (\u00e9dition 2016) \n                    www.securite-sociale.fr\/IMG\/pdf\/chiffres_cles_ed_2016_web.pdf\n                    \n                  . Accessed 2016."},{"issue":"2","key":"6933_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1600-0447.1997.tb09911.x","volume":"96","author":"CC Kan","year":"1997","unstructured":"Kan CC, Breteler MH, Zitman FG. High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand. 1997;96(2):85\u201393.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"6933_CR39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/009286150503900308","volume":"39","author":"CI Neutel","year":"2005","unstructured":"Neutel CI, Walop W. Drug utilization by men and women: why the differences? Drug Inf J. 2005;39(3):299\u2013310.","journal-title":"Drug Inf J"},{"issue":"2","key":"6933_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.comppsych.2003.12.007","volume":"45","author":"Cornelis C Kan","year":"2004","unstructured":"Kan C, Hilberink S, Breteler M: Determination of the Main Risk Factors for Benzodiazepine Dependence Using a Multivariate and Multidimensional Approach, vol. 45; 2004.","journal-title":"Comprehensive Psychiatry"},{"issue":"2","key":"6933_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pds.1006","volume":"14","author":"TB Ngoundo-Mbongue","year":"2005","unstructured":"Ngoundo-Mbongue TB, Niezborala M, Sulem P, Briant-Vincens D, Bancarel Y, Jansou P, Chastan E, Montastruc JL, Lapeyre-Mestre M. Psychoactive drug consumption: performance-enhancing behaviour and pharmacodependence in workers. Pharmacoepidemiol Drug Saf. 2005;14(2):81\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"6933_CR42","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1176\/appi.ajp.161.4.654","volume":"161","author":"M Valenstein","year":"2004","unstructured":"Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatr. 2004;161(4):654\u201361.","journal-title":"Am J Psychiatr"},{"key":"6933_CR43","unstructured":"ANSM: Point d'information. Plan d\u2019actions de l\u2019ANSM visant \u00e0 r\u00e9duire le m\u00e9susage des benzodiaz\u00e9pines. 2012."},{"key":"6933_CR44","unstructured":"HAS: Modalit\u00e9s d'arr\u00eat des benzodiaz\u00e9pines et m\u00e9dicaments apparent\u00e9s chez le patient \u00e2g\u00e9. 2007."},{"key":"6933_CR45","unstructured":"HAS: Arr\u00eat des benzodiaz\u00e9pines et m\u00e9dicaments apparent\u00e9s: d\u00e9marche du m\u00e9decin traitant en ambulatoire. 2015."},{"key":"6933_CR46","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/j.respe.2016.03.035","volume":"64","author":"A Panes","year":"2016","unstructured":"Panes A, Lassalle R, Bernard M-A, Dureaud-Pournin C, Pariente A, Fourrier-R\u00e9glat A. Misuse of benzodiazepines in the French population: a cohort study in the \u00c9chantillon Gen\u00e9raliste de B\u00e9n\u00e9ficiaires between 2007 and 2012. Revue d'epidemiologie et de sante publique. 2016;64:S132\u20133.","journal-title":"Revue d'epidemiologie et de sante publique"},{"issue":"12","key":"6933_CR47","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147\u201357.","journal-title":"N Engl J Med"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-6933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-019-6933-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-6933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T23:08:22Z","timestamp":1589324902000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-019-6933-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6933"],"URL":"https:\/\/doi.org\/10.1186\/s12889-019-6933-8","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"18 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The CONSTANCES cohort has obtained the authorization of the National Data Protection Authority (Commission Nationale de l\u2019Informatique et des Libert\u00e9s, no.910486) and was approved by the Institutional Review Board of the National Institute for Medical Research \u2013 INSERM (no. 01\u2013011). Written informed consent was received from all of the subjects in the CONSTANCES cohort.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Guillaume Airagnes has received speaker and consulting fees from Lundbeck and Pfizer. C\u00e9dric Lemogne has received speaker and consulting fees from Daiichi- Sankyo, Janssen, Lundbeck, Otsuka Pharmaceuticals and Servier. Fr\u00e9d\u00e9ric Limosin has received speaker and consulting fees from Astra Zeneca, Euth\u00e9rapie-Servier, Janssen, Lundbeck, Otsuka Pharmaceuticals and Roche. Marcel Goldberg, Nicolas Hoertel, Yves Roquelaure and Marie Zins have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"566"}}